There are many active research projects accessing and applying shared ADNI data. Use the search above to find specific research focuses on the active ADNI investigations. This information is requested annually as a requirement for data access.
| Principal Investigator | |
| Principal Investigator's Name: | Madison Honey |
| Institution: | Amsterdam UMC |
| Department: | Laboratory Medicine |
| Country: | |
| Proposed Analysis: | In our analysis we aimed to develop individualized predictions for risk of developing Alzheimer’s disease (AD) dementia in a memory clinic population of individuals with either subjective cognitive decline (SCD) or mild cognitive impairment (MCI), using plasma phosphorylated-tau-181 (pTau181), amyloid beta1-42/1-40 (Aβ42/40), glial fibrillary acidic protein (GFAP) and/or neurofilament light (NfL). From the Amsterdam Dementia Cohort we included 303 individuals with SCD (age 61±9 years, n=126(42%) female, MMSE 28±1) and 250 with MCI (age 65±7 years, n=89(36%) female, MMSE 27±2), who had annual follow-up visits for re-evaluation of diagnosis (average follow-up duration: 2.7±1.7 years) and all plasma biomarkers measured at baseline using Simoa. We found that GFAP and pTau181 add prognostic value to a basic model of age, sex and MMSE, and this model including the plasma markers could be used to calculate 1, 3, and 5-year individualized risk scores for progression to AD dementia. Using data of ADNI, we now would like to externally validate our models. |
| Additional Investigators |
